UBS cuts price target on Bayer on weak outlook

Investing.com -  UBS cuts price target on Bayer AG NA (ETR:BAYGN )after the German pharmaceutical and agricultural giant posted mixed third-quarter results and issued downbeat earnings forecast for 2025.

Bayer’s pharmaceutical division is grappling with headwinds, including the erosion of revenues from its blood thinner Xarelto. While recent drug launches such as acoramadis and elinzanetant aim to fill the gap, analysts say they are not expected to offset the margin decline.

UBS cut sum-of-the-parts (SOTP) derived price target to €22 from €30.

The biggest adjustment came in the valuation of the seeds business, with its per-share contribution falling to €20.5 from €25.9, reflecting reduced sales expectations, lower trait income, and a weaker valuation multiple compared to peers. Analysts also raised Bayer’s conglomerate discount to 50% from 40%, citing continued uncertainty around free cash flow recovery and litigation risks.

Despite near-term challenges, analysts see some long-term promise in Bayer’s crop science business, particularly its short-stature corn, which has been well received in early markets. The pharma division’s newer drugs, including Nubeqa and Kerendia, continue to perform well, and the launch of a high-dose version of eye treatment Eylea is extending its franchise.

However, with Xarelto revenue erosion expected to persist for at least two years and a limited mid-term pipeline, analysts remain cautious.

Source: Investing.com

Publicații recente
Oklo target nearly doubled at Wedbush on AI-driven demand for nuclear energy
24.01.2025 - 18:00
Crypto markets lose steam after Trump's first policy move
24.01.2025 - 18:00
Combination of Google's TPU-DeepMind units may be worth $700 bn - DA Davidson
24.01.2025 - 18:00
British American Tobacco, Altria shares rise after menthol ban proposal dropped
24.01.2025 - 18:00
Morocco stocks higher at close of trade; Moroccan All Shares up 0.34%
24.01.2025 - 18:00
Commerzbank says no talks with UniCredit until specific proposal made
24.01.2025 - 18:00
Venture Global aims for $64 billion valuation at debut in test for energy IPOs
24.01.2025 - 18:00
Intuitive Machines stock surges on NASA contract award
24.01.2025 - 18:00
International Paper's $7.2 billion acquisition of DS Smith gets EU approval
24.01.2025 - 18:00
Short-term stock optimism soars among retail investors, AAII survey shows
24.01.2025 - 18:00
Venture Global shares likely to open up to 6% above IPO price
24.01.2025 - 18:00
Intuitive Surgical, American Express Stir Friday's Market Cap Stock Movers
24.01.2025 - 18:00
BMW joins Chinese EV makers in filing EU court challenge to tariffs
24.01.2025 - 18:00
Turkey stocks lower at close of trade; BIST 100 down 0.08%
24.01.2025 - 18:00
Diageo stock jumps on possible Guinness sale
24.01.2025 - 18:00

© Analytic DC. All Rights Reserved.

new
Analiza pieței Cum va afecta raportul NFP de mâine cursul de schimb al dolarului american?